SPC
EIGR

Slate Path Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Slate Path Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,500
Closed -$1.92M – 52
2022
Q3 		$1.92M Hold
8,500
– – 0.12% 39
2022
Q2 		$1.61M Hold
8,500
– – 0.1% 37
2022
Q1 		$2.12M Buy
+8,500
New +$1.34M 0.11% 35

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Slate Path Capital's EIGR Position: Q4 2022 in Review

Slate Path Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 8,500 shares — an estimated $1.92M sold.

Slate Path Capital first reported a position in EIGR in Q1 2022 and held it in 3 quarters. The position peaked at $2.12M in Q1 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Slate Path Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Slate Path Capital sold 8,500 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $1.92M.
  • Slate Path Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2022 and held it in 3 quarters.
  • Slate Path Capital's Eiger BioPharmaceuticals, Inc. position peaked at $2.12M in Q1 2022.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Slate Path Capital's 13F filing for Q4 2022, filed 14 Feb 2023.